Literature DB >> 3718833

Importance of quantitative histology of bone changes in monoclonal gammopathy.

R Bataille, D Chappard, C Alexandre, P Dessauw, J Sany.   

Abstract

Quantitative histology of bone changes, using undecalcified transiliac bone biopsies (UTBB), was performed blindly in 46 individuals with monoclonal gammopathy (MG), including 17 with MG of undetermined significance (MGUS) and 29 with overt multiple myeloma (MM). Three MGUS presented an excess of osteoclastic resorption (OR) in the vicinity of clusters of tumour cells and developed overt B cell malignancies, chronic lymphocytic leukaemia, Waldenström's disease and MM respectively. On the other hand, MGUS with normal OR remained stable (median follow-up = 28 months), with one exception who developed a systemic amyloidosis. In MM, excessive OR was only observed in areas invaded by myeloma cells. OR was frequently normal in active MM lacking myeloma cells in UTBB. Active MM without lesions on radiography had excessive OR. IgA and pure Bence Jones MM appeared more osteoclastic than IgG cases (P less than 0.05). Of major interest was the finding that one third of MM presented histological bone changes similar to osteoporosis, osteosclerosis or osteoblastic metastasis. Two major findings must be emphasized from the current data: UTBB could be of major interest for the early detection of a B cell malignancy; heterogeneity of myeloma bone condition is unexpected. If some changes appear directly related to the tumour (i.e. excessive OR or osteoblastic dysfunction), some others are probably accidentally associated with it (i.e. osteoporosis), both needing treatment other than chemotherapy.

Entities:  

Mesh:

Year:  1986        PMID: 3718833      PMCID: PMC2001420          DOI: 10.1038/bjc.1986.136

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Effect of osteoclast activating factor from human leukocytes on bone metabolism.

Authors:  L G Raisz; R A Luben; G R Mundy; J W Dietrich; J E Horton; C L Trummel
Journal:  J Clin Invest       Date:  1975-08       Impact factor: 14.808

2.  Pseudomyeloma. Is association of severe osteoporosis with serum monoclonal gammopathy an entity or a coincidence?

Authors:  J E Maldonado; B L Riggs; E D Bayrd
Journal:  Arch Intern Med       Date:  1975-02

3.  Fanconi syndrome in adults. A manifestation of a latent form of myeloma.

Authors:  J E Maldonado; J A Velosa; R A Kyle; R D Wagoner; K E Holley; R M Salassa
Journal:  Am J Med       Date:  1975-03       Impact factor: 4.965

4.  Controlled environment culture of bone marrow explants from human myeloma.

Authors:  S Gailani; W F McLimans; G R Mundy; A Nussbaum; O Roholt; R Zeigel
Journal:  Cancer Res       Date:  1976-04       Impact factor: 12.701

5.  Evidence for the secretion of an osteoclast stimulating factor in myeloma.

Authors:  G R Mundy; L G Raisz; R A Cooper; G P Schechter; S E Salmon
Journal:  N Engl J Med       Date:  1974-11-14       Impact factor: 91.245

6.  Pseudomyeloma.

Authors:  E Buonocore; A Solomon; H E Kerley
Journal:  Radiology       Date:  1970-04       Impact factor: 11.105

7.  Unusual B-cell cancers that produce bone-resorbing factors and can mimic multiple myeloma.

Authors:  J F Rossi; R Bataille
Journal:  N Engl J Med       Date:  1985-05-02       Impact factor: 91.245

8.  Monoclonal gammopathy of undetermined significance. Natural history in 241 cases.

Authors:  R A Kyle
Journal:  Am J Med       Date:  1978-05       Impact factor: 4.965

9.  Comparison of bone scintigraphy and radiography in multiple myeloma.

Authors:  J M Woolfenden; M J Pitt; B G Durie; T E Moon
Journal:  Radiology       Date:  1980-03       Impact factor: 11.105

10.  A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

Authors:  B G Durie; S E Salmon
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

View more
  12 in total

1.  Targeting bone as a therapy for myeloma.

Authors:  Ping Wu; Gareth J Morgan
Journal:  Cancer Microenviron       Date:  2011-08-11

2.  Bone marrow biopsy in monoclonal gammopathies: correlations between pathological findings and clinical data. The Cooperative Group for Study and Treatment of Multiple Myeloma.

Authors:  A Riccardi; G Ucci; R Luoni; A Castello; A Coci; U Magrini; E Ascari
Journal:  J Clin Pathol       Date:  1990-06       Impact factor: 3.411

3.  Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma.

Authors:  R Bataille; D Chappard; C Marcelli; P Dessauw; P Baldet; J Sany; C Alexandre
Journal:  J Clin Invest       Date:  1991-07       Impact factor: 14.808

Review 4.  Dendritic cells and malignant plasma cells: an alliance in multiple myeloma tumor progression?

Authors:  Marco Tucci; Stefania Stucci; Sabino Strippoli; Franco Dammacco; Franco Silvestris
Journal:  Oncologist       Date:  2011-06-09

Review 5.  Tumor-host cell interactions in the bone disease of myeloma.

Authors:  Jessica A Fowler; Claire M Edwards; Peter I Croucher
Journal:  Bone       Date:  2010-07-13       Impact factor: 4.398

Review 6.  Osteosclerotic myeloma with polyneuropathy and hypocalcemia.

Authors:  C Ludescher; K Grünewald; F Fend; O Dietze; J Thaler; K W Schmid
Journal:  Blut       Date:  1989-04

7.  Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation.

Authors:  Scott A Ely; Daniel M Knowles
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

8.  Osteoclast cytomorphometry demonstrates an abnormal population in B cell malignancies but not in multiple myeloma.

Authors:  D Chappard; J F Rossi; R Bataille; C Alexandre
Journal:  Calcif Tissue Int       Date:  1991-01       Impact factor: 4.333

9.  Multiple myeloma: effect of daily dichloromethylene bisphosphonate on skeletal complications.

Authors:  M R Clemens; K Fessele; M E Heim
Journal:  Ann Hematol       Date:  1993-03       Impact factor: 3.673

10.  The role of the BMP signaling antagonist noggin in the development of prostate cancer osteolytic bone metastasis.

Authors:  Chiara Secondini; Antoinette Wetterwald; Ruth Schwaninger; George N Thalmann; Marco G Cecchini
Journal:  PLoS One       Date:  2011-01-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.